Qui sommes-nous? Urgences Traitements Infos médecins Centre de recherche Faire un don Liens
  Rechercher
Home  <  Centre de recherche  <  Publications 2010  <  Publications 2006 Plan d'accèsPlan du siteImprimer www.chuv.ch
Info.onco@chuv.ch
 

Publications : 2006
1: Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Sendler A, Siewert JR, Peschel C, Lordick F.
    Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Ann Thorac Surg.; 82 : 293-7, 2006.
2: Alghisi C and Rüegg C.
    Vascular integrins in tumor angiogenesis: mediators and therapeutic targets Endothelium;
13 : 113-35, 2006.
3: Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.
    New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
J Immunol.; 177 : 1670-8, 2006.
4: Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S.
    Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.
J Immunol Methods.; 309 : 192-9, 2006.
5: Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P.
    Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Eur J Immunol.; 36 (7) : 1805-14, 2006.
6: Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Agha IY, Bourhis JH, Garderet L, Pegourie B, Dumontet C
    nter-Groupe Francophone du Myelome (IFM) : Maintenance therapy with thalidomide improves survival in patients with multiple
myeloma. Blood; 108 (10) : 3289-94, 2006.
7: Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Lienard D, Romero P, Speiser DE.
    Ex vivo detectable human CD8 T-cell responses to cancer-testis-antigens. Cancer Research; 66 (4) : 1912-6, 2006.
Cancer Research; 66 (4) : 1912-6, 2006.
8: Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Blay JY;
    Groupe Sarcome Francais : Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Int J Cancer.; 119 (3) : 706-11, 2006.
9: Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Haicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cernzy T, Ris HB.
    Prognostic factors affecting long-term outcomes in patients with reseceted stage IIIA pN2 non-small-cell lung cancer.: 5-year follow-up of a phase II study.
Br J Cancer 24:1099-106, 2006
10: Bieler G., Hasmim M., Monnier Y., Imaizumi N., Ameyar M., Bamat J., Ponsonnet L., Chouaib S., Grell M., Goodman S. L., Lejeune F. and Rüegg C.
    Distinctive role of integrin-mediated adhesion in TNF-induced PKB and NF-kB activation and relevance to endothelial cell survival
Oncogene; Mar 19, 2007
11: Buchegger F, Antonescu C, Bischof Delaloye A, Helg C, Kovacsovics T, Kosinski M, Mach J-P and Ketterer N.
    Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.
Br.J. Cancer; 94 : 1770-6, 2006.
12: Charkravarti A, Erkkinnen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS.
    Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Clin Cancer Res 12:4738-46, 2006
13: Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I.
    EORTC Soft Tissue and Bone Sarcoma Group; The Italian Sarcoma Group; Australasian GastroIntestinal Trials Group : KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors.
Eur J Cancer.; 42 (8) : 1093-103, 2006.
14: Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R
    New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Neurosurg Focus 20:E6, 2006
15: EORTC GI group and ICCG (Lausanne : S. Leyvraz)
    Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
Ann. Oncol.; 17, 262-269, 2006.
16: Ganière V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S, Stupp R.
    Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide (Case report and CME).
Nat Clin Pract Oncol 3: 339-343, 2006
17: Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P.
    Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Blood; 107 : 3474-80, 2006.
18: Hasmim M., Bieler G. and Rüegg C. Zoledronate
    Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways J. Thromb Hemost; 5 : 166-73, 2007.
Thromb Hemost; 5 : 166-73, 2007.
19: Hegi ME, Stupp R.
    should they influence treatment ?
Curr Oncol Rep 8:54-57, 2006
20: International Breast Cancer Study Group IBCSG (Lausanne : S. Leyvraz)
    Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer : first results of International Breast Cancer Study Group, Trial 10-93.
J. Clin. Oncol.; 24 : 337-344, 2006.
21: Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M.
    A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Cancer Chemotherapy & Pharmacology, 57 (4) : 533-9, 2006.
22: Krueger T, Kuemmerle A, Andrejevic-Blant S, Yan H, Pan Y, Ballini JP, Klepetko W, Decosterd LA, Stupp R, Ris HB.
    Antegrade versus retrograde isolated lung perfusion. Doxorubicin uptake and distribution in a sarcoma model.
Ann Thorac Surg 82:2024-2030, 2006
23: Krueger T, Kuemmerle A, Kosinski M, Denys A, Magnusson L, Stupp R, Delaloye AB, Klepetko W, Decosterd L, Ris HB, Dusmet M
    Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: Evaluation of different cytostatic lung perfusion techniques in a porcine model.
J Thorac Cardiovasc Surg, 132 : 304-311, 2006
24: Lejeune F., Monnier Y. and Rüegg C.
    Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with COX-2 inhibitor
Melanoma Res.; 16 : 263-265, 2006.
25: Lejeune F.J., Liénard D., Matter M. and Rüegg C.
    Efficiency of recombinant human TNF in human cancer therapy
Cancer Immunity; 6 : 6, 2006.
26: Lejeune FJ, Ruegg C.
    Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
Bull Cancer.;93 (8) : E90-E100, 2006.
27: Leyvraz S, Zweifel M, Jundt G, Lissoni A, Cerny T, Sessa C, Fey M, Dietrich D, Honegger HP
    Swiss Group for Clinical Cancer Research : Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Ann Oncol.; 17 (4): 646-51, 2006.
28: Leyvraz S., Hermann R., Guillou L., Honegger H.P., Christinat A., Fey M.F., Sessa C., Wernli M., Cerny T., Dietrich D., Pestalozzi B.
    Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Br J Cancer.; 95 (10) : 1342-7, 2006.
29: Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R
    Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
J Clin Oncol 24:2563-2569, 2006
30: Moreau P, Hullin C, Garban F, Yacoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto Jj, Bataille R, Harousseau JL.
    Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Blood, 107 : 397-403, 2006.
31: Mutter N, Stupp R.
    Temozolomide, a milestone in neuro-oncology, and beyond?
Exp Rev Anticacner Ther 6:1187-204, 2006
32: Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche Ph, Azria D, Mirimanoff R-O, Zouhair A
    Feasibility and efficacy of subcutaneous Amifostine in head and neck cancer patients treated with curative accelerated concomitant boost radiotherapy.
Arch Otolaryngol Head Neck Surg.; 132 : 141-145, 2006.
33: Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion KM, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T.
    High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
Ann Oncol; 17 : 1479-88, 2006.
34: Perey L., Paridaens R., Hawle H., Zaman K., Nolé F., Wildiers H., Fiche M., Dietrich D., Clément P., Köberle D., Goldhirsch A., and Thürlimann B.
    Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Ann. Onc.; 18 : 64-69, 2007.
35: Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S.
    Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Ann Oncol. ; 17 (4) : 578-83, 2006.
36: Peters S,Luthi F, Leyvraz S
    Urgences oncologiques : chapitres choisis.
Forum Med Suisse.; 6 : 718-725, 2006.
37: Rüegg C.
    leukcocytes and angiogenesis in cancer: fatal attraction (Editorial, Guest editor)
J Leuk Biol; 80 : 682-4, 2006.
38: Rüegg, M. Hasmim, F. Lejeune and G.C Alghisi
    Anti-angiogenic peptides and proteins: from experimental tools to clinical drugs Biochim Biophys
Acta Rev on Cancer; 1765 : 155-77, 2006.
39: Salzberg M, Borner M, Bauer J, Morant R, Rauch D, Rochlitz C.
    rastuzumb (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder : report on 7 patients.
European Journal of Cancer, 42 (15) : 2660-1, 2006.
40: Scolozzi P, Maret N, Bouzourene H, Luthi F, Bauer J, Jaques B, Lombardi T.
    Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving the maxillary gingiva.
J Oral Pathol Med.; 35 : 579-581, 2006.
41: Stupp R, Hegi ME, van den Bent MJ, Weller M, Mirimanoff RO, Cairncross JG.
    Cairncross JG. Changing paradigms—an update on the multidisciplinary management of malignant glioma.
Oncologist 11:165-180, 2006
42: Voeffray M., Pannatier A., Stupp R., Fucina N., Leyvraz S., Wasserfallen J.B.
    Effect of computerization on the quality and safety of chemotherapy prescription.
Qual. Saf. Health Care; 15 : 418-421, 2006.
43: Voelter V, Appay V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.
    Combination of transient lymphodepletion with Busulfan and Fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
J Immunotherapy; 30 : 240-250, 2007.
44: Voelter V, Zouhair A, Vuilleumier H, Matter M, Bouzourene H, Leyvraz S, Bauer J, Coucke P, Stupp R.
    CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results fomr a phase II study.
Br J Cancer, 95 : 710-716, 2006
45: Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T.
    Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
Br J Clin Pharmacol.; 62 (1) : 97-112, 2006.
46: Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Ruegg C.
    Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Int J Cancer.; 118 (3) : 755-64, 2006.
47: Zweifel M. and Rüegg C.
    Tumorangiogenese-Hemmung in der onkologischen Therapie: heutiger Stand und offene Fragen Onkologie; 2 : 32-36, 2006.
Onkologie; 2 : 32-36, 2006.
48: van den Bent MJ, Hegi ME, Stupp R.
    Recent development in the use of chemotherapy in brain tumours.
Eur J Cancer 42:582-588, 2006

Retour en haut de la page
Dernière modification le 05.08.2011